Greg Harrison
Stock Analyst at Scotiabank
(2.20)
# 2,640
Out of 4,754 analysts
70
Total ratings
42.86%
Success rate
-2.89%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Greg Harrison
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BEAM Beam Therapeutics | Maintains: Sector Perform | $24 → $25 | $26.33 | -5.03% | 4 | Mar 3, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Sector Outperform | $49 → $52 | $34.27 | +51.76% | 5 | Feb 21, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Sector Outperform | $310 → $300 | $244.90 | +22.50% | 3 | Feb 14, 2025 | |
| TVTX Travere Therapeutics | Maintains: Sector Outperform | $27 → $32 | $21.04 | +52.13% | 8 | Feb 12, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Sector Perform | $433 → $450 | $484.39 | -7.10% | 5 | Feb 11, 2025 | |
| IRON Disc Medicine | Maintains: Sector Outperform | $70 → $73 | $55.69 | +31.08% | 3 | Jan 22, 2025 | |
| KROS Keros Therapeutics | Maintains: Sector Outperform | $44 → $41 | $11.23 | +265.26% | 5 | Jan 16, 2025 | |
| AGIO Agios Pharmaceuticals | Maintains: Sector Outperform | $53 → $75 | $33.87 | +121.43% | 4 | Dec 9, 2024 | |
| APLS Apellis Pharmaceuticals | Maintains: Sector Perform | $35 → $30 | $24.70 | +21.46% | 2 | Nov 6, 2024 | |
| VERA Vera Therapeutics | Initiates: Sector Outperform | $60 | $29.54 | +103.11% | 1 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $18 | $6.22 | +189.39% | 1 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $30 | $15.15 | +98.09% | 4 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $6 | $1.82 | +230.58% | 1 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $50 | $9.18 | +444.66% | 3 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $22 | $6.61 | +233.08% | 1 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $13 → $15 | $1.87 | +702.35% | 3 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $303 → $280 | $318.51 | -12.09% | 1 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $89 → $91 | $10.23 | +789.78% | 2 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $9 → $12 | $7.70 | +55.84% | 3 | May 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $5 → $1.5 | $1.00 | +50.00% | 1 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $39 | $8.94 | +336.24% | 1 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $3 | $8.15 | -63.17% | 1 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $70 | $3.04 | +2,199.98% | 1 | Sep 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $8 | $13.72 | -41.69% | 1 | Jun 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $67 → $54 | $20.72 | +160.62% | 1 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $18 → $6 | $0.82 | +629.22% | 5 | Mar 14, 2022 |
Beam Therapeutics
Mar 3, 2025
Maintains: Sector Perform
Price Target: $24 → $25
Current: $26.33
Upside: -5.03%
BridgeBio Pharma
Feb 21, 2025
Maintains: Sector Outperform
Price Target: $49 → $52
Current: $34.27
Upside: +51.76%
Alnylam Pharmaceuticals
Feb 14, 2025
Maintains: Sector Outperform
Price Target: $310 → $300
Current: $244.90
Upside: +22.50%
Travere Therapeutics
Feb 12, 2025
Maintains: Sector Outperform
Price Target: $27 → $32
Current: $21.04
Upside: +52.13%
Vertex Pharmaceuticals
Feb 11, 2025
Maintains: Sector Perform
Price Target: $433 → $450
Current: $484.39
Upside: -7.10%
Disc Medicine
Jan 22, 2025
Maintains: Sector Outperform
Price Target: $70 → $73
Current: $55.69
Upside: +31.08%
Keros Therapeutics
Jan 16, 2025
Maintains: Sector Outperform
Price Target: $44 → $41
Current: $11.23
Upside: +265.26%
Agios Pharmaceuticals
Dec 9, 2024
Maintains: Sector Outperform
Price Target: $53 → $75
Current: $33.87
Upside: +121.43%
Apellis Pharmaceuticals
Nov 6, 2024
Maintains: Sector Perform
Price Target: $35 → $30
Current: $24.70
Upside: +21.46%
Vera Therapeutics
Oct 16, 2024
Initiates: Sector Outperform
Price Target: $60
Current: $29.54
Upside: +103.11%
Oct 16, 2024
Initiates: Sector Outperform
Price Target: $18
Current: $6.22
Upside: +189.39%
Oct 16, 2024
Initiates: Sector Outperform
Price Target: $30
Current: $15.15
Upside: +98.09%
Oct 16, 2024
Initiates: Sector Outperform
Price Target: $6
Current: $1.82
Upside: +230.58%
Oct 16, 2024
Initiates: Sector Outperform
Price Target: $50
Current: $9.18
Upside: +444.66%
Oct 16, 2024
Initiates: Sector Outperform
Price Target: $22
Current: $6.61
Upside: +233.08%
Aug 8, 2024
Upgrades: Buy
Price Target: $13 → $15
Current: $1.87
Upside: +702.35%
Aug 1, 2024
Maintains: Underperform
Price Target: $303 → $280
Current: $318.51
Upside: -12.09%
Jun 13, 2023
Maintains: Buy
Price Target: $89 → $91
Current: $10.23
Upside: +789.78%
May 1, 2023
Upgrades: Neutral
Price Target: $9 → $12
Current: $7.70
Upside: +55.84%
Apr 28, 2023
Downgrades: Underperform
Price Target: $5 → $1.5
Current: $1.00
Upside: +50.00%
Mar 7, 2023
Initiates: Buy
Price Target: $39
Current: $8.94
Upside: +336.24%
Nov 8, 2022
Downgrades: Underperform
Price Target: $3
Current: $8.15
Upside: -63.17%
Sep 29, 2022
Initiates: Buy
Price Target: $70
Current: $3.04
Upside: +2,199.98%
Jun 8, 2022
Upgrades: Neutral
Price Target: $8
Current: $13.72
Upside: -41.69%
Mar 16, 2022
Maintains: Buy
Price Target: $67 → $54
Current: $20.72
Upside: +160.62%
Mar 14, 2022
Downgrades: Underperform
Price Target: $18 → $6
Current: $0.82
Upside: +629.22%